Cellix Signs Distribution Agreement With Chromaphor
Chromaphor is likely to handle sales and service in Germany
Cellix has entered into a distribution agreement with Germany-based Chromaphor Analysen-Tecknik, to handle sales and service agreements for Cellix products in Germany.
Vivienne Williams, chief executive officer of Cellix, said, ''We selected Chromaphor as our distribution partner in Germany because of their proven sales methods. Chromaphor has exceptional insights into the cell biology markets and a customer base that is an ideal fit for our products.'
Hugo Ostermann, managing director of Chromaphor, said: We are very excited about bringing Cellix’s unique products to our customers in Germany. The VenaFlux Platform and accessories provides exciting new tools for our customers and fits very well with our existing product portfolio."
Dublin, Ireland based Cellix is a privately held instrumentation and cell-based assay company.
Chromaphor Analysen-Tecknik is a German distributor and systems integrator for new scientific instruments, reagents and accessories for the life sciences market.
Related Insight
Suppliers Directory
Pharmassist – Pharmaceutical Contract Research Organisation
Pharmassist is a contract research organisation located in Athens, Greece, providing services in the areas of regulatory affairs, pharmacovigilance, clinical trials, medical economics and biostatistics.
Contract Research & Services > Contract Services > Suppliers
HighTable- Gathering and Sharing Expertise
HighTable helps you gather and share expertise. In a world where everyone's connected, it's surprisingly difficult to find insights from people who know what they’re talking about. Would you rather go straight to the source or search the internet for hours?
Contract Research & Services > Contract Services > Suppliers
EXTEDO - Key Services and Solutions Provider in eRegulatory Affairs
EXTEDO is the key solutions and services provider in the field of eRegulatory Affairs.
Contract Research & Services > Contract Services > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Contract Services Intelligence
Products and Services
Published by PFC Pharma Focus
Contract Research & Services > Contract Services > White Papers
Finding the Right Contract Manufacturer
Published by Vetter Pharma International
Contract Research & Services > Contract Services > White Papers
2011 ILS Capabilities and Experience
Published by Investigator Location Services
Contract Research & Services > Contract Services > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.